Disc Medicine, Inc. (NASDAQ: IRON) is a clinical-stage biopharmaceutical company developing therapies for hematologic diseases caused by dysregulated iron homeostasis. Its pipeline targets both rare and chronic blood disorders with novel mechanisms of action. Disc Medicine’s shares move with clinical trial results, regulatory updates, and investor sentiment toward innovative rare-disease treatments.
最新股票文章

英伟达股票预测:第三方价格目标
自2025年年初以来,截至4月中旬,英伟达(NVDA)股价下跌约27.37%,但同比上涨26.48%。基于4月22日开盘价98.78美元,自1月初以来,英伟达股票波动显著,受到行业特定因素以及围绕美国贸易关税的更广泛股市不确定性影响。
17:42, 19 五月 2025


